- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Topic in appraisal
- Process:
- STA Standard
- ID number:
- 6440
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Plusultra (sirolimus gel)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Changing Faces
- Genetic Alliance UK
- Gene People
- Let’s Face It
- Myrovlytis Trust
- South Asian Health Foundation
- Specialised Healthcare Alliance
- The BHD Foundation
- Tuberous Sclerosis Association
- Professional groups
- Association of Genetic Nurses & Counsellors
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- British Society for Gene and Cell Therapy
- British Society for Genetic Medicine
- General Medical Council
- Neonatal and Paediatric Pharmacists Group
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics and Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Kidney Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Cell and Gene Therapy Catapult
- Department of Health - Northern Ireland
- Great Ormond Street Hospital
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Paediatric Neurodisability TSC Clinic, Alder Hey Children’s Hospital
- Paediatric Neurology TSC Clinic, University Hospitals Bristol
- Scottish Medicines Consortium
- TSC Team, Children’s Centre, Royal United Hospital Bath
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- British Skin Foundation
- Cochrane Skin Grup
- Dermatrust
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 May 2025 | This topic has been paused. The appraisal committee will not be held in September 2025. The topic will be rescheduled to the next available committee date. |
| 22 October 2024 | Invitation to participate |
| 24 September 2024 - 08 October 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 24 May 2024 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual